-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As of 7:01 on October 22, 2021 Beijing time, Worldometers world real-time statistics show that the cumulative number of confirmed new coronary pneumonia ( COVID-19 ) cases worldwide has exceeded 243.
New Coronary Pneumonia COVID-19 Briefing on October 21, 2021: A small number of local cases in 7 provinces in China; the United States announces children
China has provided more than 1.
China has provided more than 1.
When answering relevant questions at the regular press conference that day, Wang Wenbin said that since the outbreak of the new crown pneumonia, China has firmly upheld the attributes of a vaccine as a global public product and has done its best to provide vaccines to the international community
WHO warns: the new crown epidemic may continue until the end of 2022
WHO warns: the new crown epidemic may continue until the end of 2022 WHO warns: the new crown epidemic may continue until the end of 2022The World Health Organization said that the new crown epidemic is likely to continue until the end of 2022 because poor countries cannot obtain the vaccines they need
The World Health Organization said that the new crown epidemic is likely to continue until the end of 2022 because poor countries cannot obtain the vaccines they need
US approval of all three new hybrid crown vaccine as a booster vaccination is still the best solution pending US approval of all three new crown vaccine as a booster vaccination mixing the best solution is still pending American approval of all three new crown vaccine as a booster vaccination mix is still the best option To be determined
The US Food and Drug Administration Bureau FDA on Wednesday night approved Johnson & Johnson and Moderna's new crown vaccine as a booster, a key step for the United States to accelerate the strengthening of vaccine distribution
The US Food and Drug Administration Bureau FDA on Wednesday night approved Johnson & Johnson and Moderna's new crown vaccine as a booster, a key step for the United States to accelerate the strengthening of vaccine distribution
The FDA has so far approved all three new coronavirus vaccines available in the United States, including Pfizer, Moderna, and Johnson & Johnson, as boosters
In addition, the FDA has also approved a mixed vaccination program that uses different types of vaccines as boosters, which will provide a reference for the global booster vaccination program
According to data from the CDC of the US Centers for Disease Control and Prevention , so far, about 11.
Pfizer's new crown vaccine is as effective as 93% in preventing hospitalizations of 12 to 18-year-olds
A study released by the Centers for Disease Control and Prevention (CDC) on Tuesday showed that Pfizer's new crown vaccine is 93% effective in preventing hospitalizations for 12 to 18-year-olds
A study released by the Centers for Disease Control and Prevention (CDC) on Tuesday showed that Pfizer's new crown vaccine is 93% effective in preventing hospitalizations for 12 to 18-year-olds
French vaccine Phase III results released: "Strong immune response than AstraZeneca" Phase III results of French vaccine released: " Immune response stronger than AstraZeneca" Phase III results of French vaccine released: " Immune response stronger thanAstraZeneca""Immunity
Good news came from the French vaccine on October 18th: Valneva, a French-Austrian joint venture biotechnology company headquartered in Nantes, France, announced that the company’s vaccine candidate "VLA2001" Phase III clinical trial preliminary results "Positive", "Achieve the two main evaluation goals"
Good news came from the French vaccine on October 18th: Valneva, a French-Austrian joint venture biotechnology company headquartered in Nantes, France, announced that the company’s vaccine candidate "VLA2001" Phase III clinical trial preliminary results "Positive", "Achieve the two main evaluation goals"
On September 13, the United Kingdom announced the cancellation of pre-orders for 100 million doses, causing Varneva’s share price to plummet by 40%, from 19.
"The results of the Phase III clinical trial for a total of 4,012 volunteers over the age of 18 in 26 locations in the United Kingdom showed that the VLA2001 vaccine produced more neutralizing antibodies than the AstraZeneca new crown vaccine.
.
.
Two weeks after the second dose (Day 43), the neutralizing antibody conversion rate of the two groups of vaccinators (30 years old and above) was higher than 95%
.
"
Adam Finn, principal investigator of the Valnevar vaccine clinical trial and a professor of pediatrics at the University of Bristol in the United Kingdom, pointed out that the technology used in the VLA2001 vaccine is "more traditional than the current vaccines in the United Kingdom and European and American countries.
The test results also show that the candidate vaccine is expected to be in Play an important role in the fight against the new crown epidemic"
.
The test results also show that the candidate vaccine is expected to be in Play an important role in the fight against the new crown epidemic"
.
Warnevard CEO Thomas Lingelbach said, "The test results prove the many advantages of inactivated vaccines.
" He revealed that the company will file the VLA2001 vaccine as soon as possible and "provide new options for those who have not yet been vaccinated
.
"
" He revealed that the company will file the VLA2001 vaccine as soon as possible and "provide new options for those who have not yet been vaccinated
.
"
National Health Commission: 21 new confirmed cases of new coronary pneumonia on the 20th, including 13 local cases
National Health Commission: 21 new confirmed cases of new coronary pneumonia on the 20th, including 13 local cases.National Health Commission: 21 new confirmed cases of new coronary pneumonia on the 20th, including 13 local cases
The National Health Commission notified on the 21st that from 0-24 o'clock on October 20, 31 provinces (autonomous regions, municipalities) and the Xinjiang Production and Construction Corps reported 21 new confirmed cases
.
Among them, 8 were imported cases from abroad (6 in Shanghai, 1 in Henan, and 1 in Guangdong), including 1 from asymptomatic infection to confirmed case (in Henan); 13 local cases ( 5 in Gansu, 4 in Lanzhou) Cases, 1 case in Zhangye City; 4 cases in Ningxia, including 2 cases in Wuzhong City and 2 cases in Yinchuan City; 2 cases in Inner Mongolia, both in Xilin Gol League; 2 cases in Hubei, both in county-level administrative divisions ), including 1 case from asymptomatic The infected person was converted to a confirmed case (in Gansu)
.
There were no new deaths
.
There are no new suspected cases
.
On the same day, 34 new cases were cured and discharged, and 1,300 close contacts were released from medical observation.
The number of severe cases decreased by 1 compared with the previous day
.
There are currently 421 confirmed cases imported from abroad (no severe cases), and 1 suspected case
.
A total of 9,459 confirmed cases, a total of 9,038 cured and discharged cases, and no deaths
.
As of 24:00 on October 20, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are 492 confirmed cases (no severe cases), a total of 91494 cured and discharged cases, and a total of 4636 deaths.
Reported 96,622 confirmed cases, and 1 suspected case
.
A total of 1,218,545 close contacts have been traced, and 22,383 close contacts are still under medical observation
.
31 provinces (autonomous regions and municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 27 new cases of asymptomatic infections, including 20 imported cases and 7 local cases (3 cases in Yunnan, all in Dehong Dai and Jingpo Autonomous Prefecture; 2 cases in Hebei.
All were in Xingtai City; 1 case in Hunan, in Changsha City; 1 case in Guizhou, in Zunyi City); 2 cases were converted to confirmed cases on the same day (1 case imported from abroad); 9 cases were lifted from medical observation on the same day (6 cases imported from abroad); There were 372 asymptomatic infections under medical observation (352 imported from abroad)
.
A total of 28,729 confirmed cases have been notified from Hong Kong, Macao and Taiwan
.
Among them, there were 12,305 cases in Hong Kong Special Administrative Region (12003 cases discharged, 213 deaths), 77 cases in Macau Special Administrative Region (66 discharged cases), and 16,347 cases in Taiwan (13,742 discharged cases and 846 death cases)
.
Leave a message here
